Free Newsletter
Whistleblower backlog may start clearing
Lawmakers and not-for-profit groups are pushing the feds to help clear a backlog of some 900 whistleblower lawsuits--and a sizable number of those were filed against drugmakers, the Washington Post reports.
You know the type: Consider the Merck case, which the drugmaker paid $650 to settle; it alleged that the company failed to repay Medicaid rebates. Then there was the $515 million Bristol-Myers Squibb deal, which settled claims of illegal marketing and pricing. Sen. Charles Grassley (R-IA) is among those calling for the Department of Justice to make these investigations a priority. Whether that means we'll see more pharma settlements--well, we'll just have to wait and see.
- read the WP story
Related Articles:
Court reinstates Pfizer whistleblower suit
Whistleblowers allege problems with Wyeth's Prevnar
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: